



(51) International Patent Classification:

C07K 7/62 (2006.01) A61K 38/12 (2006.01)

(21) International Application Number:

PCT/EP2019/066819

(22) International Filing Date:

25 June 2019 (25.06.2019)

(25) Filing Language:

English

(26) Publication Language:


English

(30) Priority Data:

62/689,602 25 June 2018 (25.06.2018) US

(71) Applicant: **SPERO THERAPEUTICS, INC.** [US/US];
675 Massachusetts Avenue, 14th Floor, Cambridge, Mass-
achusetts 02139 (US).(72) Inventors: **BROWN, Pamela**; c/o Cantab Anti-Infectives
Limited, 4th Floor, Reading Bridge House, George Street,
Reading Berkshire RG1 9LS (GB). **DAWSON, Michael**;
c/o Cantab Anti-Infectives Limited, 4th Floor, Reading
Bridge House, George Street, Reading Berkshire RG1 9LS
(GB). **SIMONOVIC, Mona**; c/o Cantab Anti-Infectives
Limited, 4th Floor, Reading Bridge House, George Street,Reading Berkshire RG1 9LS (GB). **BOAKES, Steven**;
c/o Cantab Anti-Infectives Limited, 4th Floor, Reading
Bridge House, George Street, Reading Berkshire RG1 9LS
(GB). **DUPERCHY, Esther**; c/o Cantab Anti-Infectives
Limited, 4th Floor, Reading Bridge House, George Street,
Reading Berkshire RG1 9LS (GB). **RIVERS, Dean**; c/o
Cantab Anti-Infectives Limited, 4th Floor, Reading Bridge
House, George Street, Reading Berkshire RG1 9LS (GB).
LESTER, Roy; c/o Cantab Anti-Infectives Limited, 4th
Floor, Reading Bridge House, George Street, Reading Berk-
shire RG1 9LS (GB). **COLEMAN, Scott**; c/o Spero Thera-
peutics, 675 Massachusetts Avenue, 14th Floor, Cambridge,
Massachusetts 02139 (US).(74) Agent: **MEWBURN ELLIS LLP**; City Tower, 40 Basing-
hall Street, London Greater London EC2V 5DE (GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: COMPOUNDS



(57) Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: formula (I) wherein -R¹⁵ is a group: formula (II) and -R¹⁶ is hydrogen; -R¹⁷ is hydrogen; -L- is a covalent bond or methylene; and -Ar is optionally substituted aryl. The groups -X-, -R¹, -R², -R³, -R⁴, and -R⁸ are as defined herein.

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*